Fabio A. Schutz

1.9k total citations · 1 hit paper
30 papers, 685 citations indexed

About

Fabio A. Schutz is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research and Molecular Biology. According to data from OpenAlex, Fabio A. Schutz has authored 30 papers receiving a total of 685 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Pulmonary and Respiratory Medicine, 9 papers in Cancer Research and 8 papers in Molecular Biology. Recurrent topics in Fabio A. Schutz's work include Renal cell carcinoma treatment (13 papers), Bladder and Urothelial Cancer Treatments (6 papers) and Cancer Genomics and Diagnostics (6 papers). Fabio A. Schutz is often cited by papers focused on Renal cell carcinoma treatment (13 papers), Bladder and Urothelial Cancer Treatments (6 papers) and Cancer Genomics and Diagnostics (6 papers). Fabio A. Schutz collaborates with scholars based in United States, Brazil and France. Fabio A. Schutz's co-authors include Toni K. Choueiri, Katherine M. Krajewski, Jyothi P. Jagannathan, Iván Pedrosa, Nikhil H. Ramaiya, Jacob Rosenberg, Joaquim Bellmunt, Yacine Salhi, Ronan Fougeray and David F. McDermott and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and The Lancet Oncology.

In The Last Decade

Fabio A. Schutz

29 papers receiving 667 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma

2023 89 citations Toni K. Choueiri, Laurence Albigès et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Fabio A. Schutz United States	11	381	299	263	177	136	30	685
Nina Wagener Germany	18	465 1.2×	176 0.6×	633 2.4×	192 1.1×	201 1.5×	48	1.0k
Opeyemi A. Jegede United States	12	341 0.9×	329 1.1×	183 0.7×	121 0.7×	153 1.1×	59	619
Ilya Tsimafeyeu Russia	15	360 0.9×	216 0.7×	325 1.2×	85 0.5×	143 1.1×	111	628
Daniel Rauch Switzerland	20	385 1.0×	711 2.4×	149 0.6×	221 1.2×	143 1.1×	53	1.1k
C. Stoffregen Germany	15	246 0.6×	264 0.9×	201 0.8×	181 1.0×	135 1.0×	41	678
Charles Schneider United States	17	301 0.8×	654 2.2×	260 1.0×	172 1.0×	282 2.1×	45	993
Brenda Dickow United States	11	280 0.7×	215 0.7×	162 0.6×	57 0.3×	94 0.7×	20	449
Farhood Alamdari Sweden	13	431 1.1×	174 0.6×	355 1.3×	232 1.3×	162 1.2×	29	669
Sara Elena Rebuzzi Italy	15	331 0.9×	394 1.3×	117 0.4×	79 0.4×	107 0.8×	67	643
Álvaro Taus Spain	18	408 1.1×	540 1.8×	223 0.8×	82 0.5×	227 1.7×	63	874

Countries citing papers authored by Fabio A. Schutz

Since Specialization

Citations

This map shows the geographic impact of Fabio A. Schutz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fabio A. Schutz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fabio A. Schutz more than expected).

Fields of papers citing papers by Fabio A. Schutz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fabio A. Schutz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fabio A. Schutz. The network helps show where Fabio A. Schutz may publish in the future.

Co-authorship network of co-authors of Fabio A. Schutz

This figure shows the co-authorship network connecting the top 25 collaborators of Fabio A. Schutz. A scholar is included among the top collaborators of Fabio A. Schutz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fabio A. Schutz. Fabio A. Schutz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Fontes, Mariane, et al.. (2022). Treatment Patterns Among Patients With Advanced Prostate Cancer in Brazil: An Analysis of a Private Healthcare System Database. World Journal of Oncology. 13(6). 350–358.

Choueiri, Toni K., Tom Powles, Laurence Albigès, et al.. (2022). LBA8 Phase III study of cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC) of IMDC intermediate or poor risk (COSMIC-313). Annals of Oncology. 33. S1430–S1431. 16 indexed citations

Monteiro, Fernando Sabino Marques, Fabio A. Schutz, Diogo Assed Bastos, et al.. (2021). Consensus on Treatment and Follow-Up for Biochemical Recurrence in Castration-Sensitive Prostate Cancer: A Report From the First Global Prostate Cancer Consensus Conference for Developing Countries. JCO Global Oncology. 7(7). 538–544. 3 indexed citations

Molin, Graziela Zibetti Dal, et al.. (2019). Risk of fatigue and anemia in patients with advanced cancer treated with olaparib: A meta-analysis of randomized controlled trials. Critical Reviews in Oncology/Hematology. 141. 163–173. 41 indexed citations

Oliveira, Cleyton Zanardo de, Andrey Soares, Denis L. Jardim, et al.. (2019). Meta-analysis of randomized clinical trials (RCT) for the adjuvant treatment of renal cell carcinoma (RCC) with vascular endothelial growth factor receptor tyrosine-kinase inhibitors (VEGFR TKIs).. Journal of Clinical Oncology. 37(15_suppl). 4579–4579. 1 indexed citations

Oliveira, Cleyton Zanardo de, Fabio Kater, Fernando Cotait Maluf, et al.. (2018). Non-metastatic castration-resistant prostate cancer (nmCRPC): Meta-analysis of efficacy and safety with novel hormonal agents apalutamide and enzalutamide. Annals of Oncology. 29. viii279–viii279. 2 indexed citations

Martini, Dylan J., Lana Hamieh, Rana R. McKay, et al.. (2018). Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events. Cancer Immunology Research. 6(4). 402–408. 54 indexed citations

Bellmunt, Joaquim, Ronan Fougeray, Jacob Rosenberg, et al.. (2013). Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy. Annals of Oncology. 24(6). 1466–1472. 115 indexed citations

Choueiri, Toni K., Youjin Je, Guru Sonpavde, et al.. (2013). Incidence and risk of treatment-related mortality in cancer patients treated with the mammalian target of rapamycin inhibitors. Annals of Oncology. 24(8). 2092–2097. 30 indexed citations

10.

Dabydeen, Donnette, Jyothi P. Jagannathan, Nikhil H. Ramaiya, et al.. (2012). Pneumonitis associated with mTOR inhibitors therapy in patients with metastatic renal cell carcinoma: Incidence, radiographic findings and correlation with clinical outcome. European Journal of Cancer. 48(10). 1519–1524. 76 indexed citations

11.

Schutz, Fabio A., Mark M. Pomerantz, Kathryn P. Gray, et al.. (2012). Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study. The Lancet Oncology. 14(1). 81–87. 44 indexed citations

12.

Richards, Christopher J., Youjin Je, Fabio A. Schutz, & Toni K. Choueiri. (2012). Meta-analysis of randomized control trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors.. Journal of Clinical Oncology. 30(5_suppl). 349–349. 2 indexed citations

13.

Dabydeen, Donnette, Jyothi P. Jagannathan, Nikhil H. Ramaiya, et al.. (2011). Pneumonitis associated with mTOR therapy in patients with metastatic renal cell carcinoma: Incidence, radiographic findings, and correlation with clinical outcome.. Journal of Clinical Oncology. 29(15_suppl). e15176–e15176. 5 indexed citations

14.

Bellmunt, Joaquim, Shamini Selvarajah, Scott J. Rodig, et al.. (2011). Identification of ALK gene alterations in urothelial carcinoma (UC).. Journal of Clinical Oncology. 29(15_suppl). 4568–4568. 1 indexed citations

15.

Werner, Lillian, Shamini Selvarajah, Barbara A. Weir, et al.. (2011). Identification of a novel urothelial carcinoma (UC) biomarker of lethality.. Journal of Clinical Oncology. 29(15_suppl). 4569–4569. 2 indexed citations

16.

Krajewski, Katherine M., Mengye Guo, Annick D. Van den Abbeele, et al.. (2011). Comparison of Four Early Posttherapy Imaging Changes (EPTIC; RECIST 1.0, Tumor Shrinkage, Computed Tomography Tumor Density, Choi Criteria) in Assessing Outcome to Vascular Endothelial Growth Factor–Targeted Therapy in Patients With Advanced Renal Cell Carcinoma. European Urology. 59(5). 856–862. 90 indexed citations

17.

Choueiri, Toni K., Fabio A. Schutz, Nathanael D. Hevelone, et al.. (2011). Thermal Ablation vs Surgery for Localized Kidney Cancer: a Surveillance, Epidemiology, and End Results (SEER) Database Analysis. Urology. 78(1). 93–98. 77 indexed citations

18.

Krajewski, Katherine M., Ronan Fougeray, Joaquim Bellmunt, et al.. (2011). Optimisation of the size variation threshold for imaging evaluation of response in patients with platinum-refractory advanced transitional cell carcinoma of the urothelium treated with vinflunine. European Journal of Cancer. 48(10). 1495–1502. 17 indexed citations

19.

Schutz, Fabio A., Wanling Xie, D.Y.C. Heng, et al.. (2011). The effect of low serum sodium on treatment outcome to vascular endothelial growth factor (VEGF)-targeted therapy in metastatic renal cell carcinoma: Results from a large international collaboration.. Journal of Clinical Oncology. 29(7_suppl). 322–322. 1 indexed citations

20.

Krajewski, Krzysztof, Ronan Fougeray, Toni K. Choueiri, et al.. (2011). Optimization of the size variation threshold for imaging evaluation of response in patients with platinum-refractory advanced transitional cell carcinoma of the urothelium treated with vinflunine.. Journal of Clinical Oncology. 29(15_suppl). 4570–4570. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact